XFOR vs. VTYX, ALTS, BTMD, CTOR, SXTC, NVCT, MCRB, LFVN, KYTX, and MEIP
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include Ventyx Biosciences (VTYX), ALT5 Sigma (ALTS), biote (BTMD), Citius Oncology (CTOR), China SXT Pharmaceuticals (SXTC), Nuvectis Pharma (NVCT), Seres Therapeutics (MCRB), Lifevantage (LFVN), Kyverna Therapeutics (KYTX), and MEI Pharma (MEIP). These companies are all part of the "pharmaceutical products" industry.
X4 Pharmaceuticals vs. Its Competitors
X4 Pharmaceuticals (NASDAQ:XFOR) and Ventyx Biosciences (NASDAQ:VTYX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.
In the previous week, X4 Pharmaceuticals and X4 Pharmaceuticals both had 2 articles in the media. Ventyx Biosciences' average media sentiment score of 1.74 beat X4 Pharmaceuticals' score of -0.78 indicating that Ventyx Biosciences is being referred to more favorably in the news media.
72.0% of X4 Pharmaceuticals shares are held by institutional investors. Comparatively, 97.9% of Ventyx Biosciences shares are held by institutional investors. 2.4% of X4 Pharmaceuticals shares are held by insiders. Comparatively, 14.5% of Ventyx Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
X4 Pharmaceuticals has higher revenue and earnings than Ventyx Biosciences. Ventyx Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
X4 Pharmaceuticals presently has a consensus target price of $34.17, suggesting a potential upside of 876.19%. Ventyx Biosciences has a consensus target price of $7.50, suggesting a potential upside of 197.62%. Given X4 Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe X4 Pharmaceuticals is more favorable than Ventyx Biosciences.
X4 Pharmaceuticals has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Ventyx Biosciences has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500.
Ventyx Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -311.15%. Ventyx Biosciences' return on equity of -48.89% beat X4 Pharmaceuticals' return on equity.
Summary
Ventyx Biosciences beats X4 Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
Get X4 Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XFOR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:XFOR) was last updated on 9/5/2025 by MarketBeat.com Staff
